Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial | MicrobiomeTrials
Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial
RecruitingPHASE4INTERVENTIONAL
Trial Details
Start: 2025-01-08Est. Completion: 2028-07-01
Enrollment target: 75 participants
Locations
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Localized Renal Pelvis and Ureter Urothelial CarcinomaLocally Advanced Bladder Urothelial CarcinomaLocally Advanced Renal Pelvis and Ureter Urothelial CarcinomaLocally Advanced Ureter Urothelial CarcinomaLocally Advanced Urothelial CarcinomaStage II Bladder Urothelial Carcinoma AJCC v6 and v7Stage II Renal Pelvis and Ureter Cancer AJCC v7Stage II Ureter Cancer AJCC v7Stage III Bladder Urothelial Carcinoma AJCC v6 and v7Stage III Renal Pelvis and Ureter Cancer AJCC v7Stage III Ureter Cancer AJCC v7
This phase III trial studies how well pembrolizumab works in treating patients with bladder cancer that has spread into …